Description
SENTREX-E is a powerful dual-action haemostatic tablet manufactured by Senen Biotech, combining Etamsylate 250mg and Tranexamic Acid 500mg in a single formulation. This combination is one of the most clinically trusted anti-bleeding regimens in Indian gynaecology and general medicine practice.
Available in a standard 10×10 blister pack, SENTREX-E is prescribed by gynaecologists, general physicians, and surgeons to manage excessive or uncontrolled bleeding conditions effectively. If you are a pharma entrepreneur looking for a high-prescription, fast-moving haemostatic tablet for your PCD Pharma Franchise portfolio, SENTREX-E is the product you need.
Understanding the Active Ingredients of Etamsylate 250mg + Tranexamic Acid 500mg Tablets
SENTREX-E works through a dual mechanism — both ingredients target bleeding from different angles, making this combination significantly more effective than single-drug therapy.
Tranexamic Acid 500mg: The Antifibrinolytic Agent
Tranexamic Acid belongs to the class of antifibrinolytic drugs. It works by blocking plasmin, an enzyme in the body responsible for breaking down blood clots. When bleeding occurs, the body naturally forms clots to stop it. However, in conditions like menorrhagia or post-surgical bleeding, the body’s clot-dissolving system becomes overactive. Tranexamic Acid puts a brake on this process, ensuring clots remain stable and bleeding is controlled efficiently.
Etamsylate 250mg: The Haemostatic Agent
Etamsylate is a well-established haemostatic (bleeding-control) drug that works at the capillary level. It enhances platelet adhesion, helping platelets stick together to form stable clots, and strengthens the walls of tiny blood vessels (capillaries), reducing their permeability and fragility. This makes it highly effective in controlling small-vessel bleeding that is common in gynaecological conditions and after surgical procedures.
Together, these two molecules provide fast, reliable, and sustained control over abnormal bleeding.
Medical Uses of Etamsylate + Tranexamic Acid Tablets
SENTREX-E is prescribed across multiple clinical settings, making it a broadly recommended product with consistent demand throughout the year:
Menorrhagia (Heavy Menstrual Bleeding)
This is the primary indication. SENTREX-E is widely prescribed by gynaecologists to manage abnormally heavy or prolonged menstrual periods that interfere with daily life. It significantly reduces blood loss without disrupting the natural menstrual cycle.
Postoperative Haemorrhage
Surgeons rely on Etamsylate + Tranexamic Acid combinations to prevent and manage excessive bleeding following surgeries, particularly abdominal, dental, and ENT procedures.
Local Fibrinolysis
In conditions where the body’s internal clot-dissolving activity is abnormally high (local fibrinolysis), Tranexamic Acid effectively stabilises existing clots and controls the bleeding.
Haematuria (Blood in Urine)
SENTREX-E may be used under medical supervision to manage haematuria caused by certain renal or bladder conditions.
Traumatic and Dental Bleeding
Post-extraction or trauma-related bleeding is effectively managed with this dual-combination formulation.
DUB: Dysfunctional Uterine Bleeding
A very common gynaecological condition, DUB, causes unpredictable and heavy bleeding. SENTREX-E is a first-line prescription choice for managing DUB in clinical practice.
Dosage and Administration (For Reference Only)
SENTREX-E should be taken strictly as directed by a registered medical practitioner. The standard adult dosage is typically one tablet two to three times daily, depending on the clinical condition and severity. Do not self-medicate.
Important Notes:
- Take the tablet with water, preferably after food, to reduce gastric discomfort
- Complete the full course as prescribed; do not stop midway
- Inform your doctor if you are on hormonal contraceptives, blood thinners, or have a history of thromboembolic conditions
Precautions and Contraindications
- Not recommended for patients with a known hypersensitivity to Tranexamic Acid or Etamsylate
- Use with caution in patients with a history of kidney disease or thromboembolic disorders
- Pregnant or breastfeeding women should use only under strict medical supervision
- Avoid concurrent use with fibrinolytic agents (blood clot-dissolving medicines)
- Patients with a history of seizures or disseminated intravascular coagulation (DIC) should inform their doctor before use
Possible Side Effects
SENTREX-E is generally well-tolerated at prescribed doses. In some cases, the following mild side effects may occur:
- Nausea or stomach upset
- Headache
- Dizziness
- Skin reactions (rare)
These side effects are usually temporary and resolve on their own. If symptoms persist or worsen, consult your physician immediately.
Why SENTREX-E is a High-Demand Product for PCD Franchise
Haemostatic tablets, especially combinations of Etamsylate and Tranexamic Acid, are among the highest-prescribed tablets in gynaecology clinics across India. Here’s why SENTREX-E makes strong business sense:
- Menorrhagia affects millions of women in India, creating a massive, consistent prescription base
- Prescribed by gynaecologists, general physicians, surgeons, and dentists — a wide prescriber network
- Year-round demand — not a seasonal product
- High repeat prescription rate, meaning patients come back every month
- Suitable for both urban clinics and semi-urban/rural medical stores
If your PCD pharma franchise territory includes any gynaecology clinics, nursing homes, or general practitioner setups, SENTREX-E will be one of your fastest-moving SKUs.
How to Apply for SENTREX-E PCD Franchise
Getting started with Senen Biotech’s PCD franchise for SENTREX-E is quick and straightforward:
- Reach out to the Senen Biotech team via phone, WhatsApp, or email
- Share your details: territory, existing business setup, and product interest
- Receive the full product list and PCD pricing for your area
- Sign the franchise agreement and receive your monopoly territory confirmation
- Place your first order and begin distribution with full marketing support
